GCM
UTHR icon

Genus Capital Management’s United Therapeutics UTHR Stock Holding History

Genus Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.48M Buy
10,115
+1,230
+14% +$693K 0.54% 58
2026
Q1 		$5.27M Buy
8,885
+4,445
+100% +$2.21M 0.6% 56
2025
Q4 		$2.16M Buy
+4,440
New +$2.07M 0.25% 98

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Genus Capital Management's UTHR Position: Q2 2026 in Review

Genus Capital Management increased its United Therapeutics (UTHR) stake by 14% in Q2 2026, buying an estimated $693K and bringing the position to 10,115 shares worth $5.48M. The position accounts for 0.54% of the portfolio, ranked #58.

Genus Capital Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 883 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Genus Capital Management held 10,115 shares of United Therapeutics worth $5.48M as of Q2 2026.
  • Genus Capital Management bought 1,230 United Therapeutics shares in Q2 2026, an estimated $693K.
  • United Therapeutics made up 0.54% of Genus Capital Management's portfolio in Q2 2026, its #58 holding.
  • Genus Capital Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 883 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Genus Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.